A new trading day began on Friday, with Prime Medicine Inc (NASDAQ: PRME) down -8.83% from the previous day of trading, before settling in for the closing price of $6.23. PRME’s price has ranged from $1.11 to $6.94 over the past 52 weeks.
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -124.13%. Meanwhile, its annual earnings per share averaged 28.25%. With a float of $91.65 million, this company’s outstanding shares have now reached $134.49 million.
Prime Medicine Inc (PRME) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Prime Medicine Inc is 48.57%, while institutional ownership is 22.12%. The most recent insider transaction that took place on Aug 01 ’25, was worth 4,950,000. In this transaction 10% Owner of this company bought 1,500,000 shares at a rate of $3.30, taking the stock ownership to the 3,262,440 shares. Before that another transaction happened on Aug 01 ’25, when Company’s Director bought 3,030,300 for $3.30, making the entire transaction worth $9,999,990. This insider now owns 6,230,300 shares in total.
Prime Medicine Inc (PRME) Latest Financial update
In its latest quarterly report, released on 9/30/2024, the company reported earnings of -0.44 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.2 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 28.25% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 20.49% during the next five years compared to -124.13% drop over the previous five years of trading.
Prime Medicine Inc (NASDAQ: PRME) Trading Performance Indicators
Here are Prime Medicine Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 3.56. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 204.06.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.60, a number that is poised to hit -0.25 in the next quarter and is forecasted to reach -0.90 in one year’s time.
